Pursuant to the Business Agreement, Apimeds Korea granted to the Company a sublicensable, royalty-bearing license to utilize all prior clinical development data associated with Apitoxin, Apitox, and …
The Company, in partnership with Assemble and Hilluck, intends to enter into separate joint ventures for the expansion and distribution of Korean cosmetics in the North American market.
The Company, in partnership with Assemble and Hilluck, intends to enter into separate joint ventures for the expansion and distribution of Korean cosmetics in the North American market.
The Company, in partnership with LK Ventures, intends to enter into a joint venture regarding the transfer of North American business rights to, and co-investment for, the K-culture experiential phot…
Reciprocal relationship from SOTK graph: ng Manager, and Vice President of Application Engineering. Mr. Cichetti has experience in lab testing, process development, project management, and has succes…
Reciprocal relationship from SOTK graph: Reciprocal relationship from APUS graph: Reciprocal relationship from SOTK graph: ng Manager, and Vice President of Application Engineering. Mr. Cichetti has …
ess development activities. Previously, Mr. Ji served as an independent director of Trinity Ventures, a venture capital firm, from August 2018 until January of 2025. Mr. Cho has served as the Chief E…
ess development activities. Previously, Mr. Ji served as an independent director of Trinity Ventures, a venture capital firm, from August 2018 until January of 2025. Mr. Cho has served as the Chief E…
ess development activities. Previously, Mr. Ji served as an independent director of Trinity Ventures, a venture capital firm, from August 2018 until January of 2025. Mr. Cho has served as the Chief E…
ess development activities. Previously, Mr. Ji served as an independent director of Trinity Ventures, a venture capital firm, from August 2018 until January of 2025. Mr. Cho has served as the Chief E…
ision, Device Solutions division of Samsung Electronics Co., Ltd. as a Staff Engineer for Firmware Development and Simulator. Since January 2025, Mr. Ji has served as an independent director of LK Ve…
Apimeds Pharmaceuticals US, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
APUS-DEBT-7810
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
APUS-DEBT-7809
Warrants outstanding: 139388
90%
xbrl warrant detail from xbrl 2025-12-31.
Apimeds Pharmaceuticals US, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Apimeds Pharmaceuticals US, Inc..
Apimeds Pharmaceuticals US, Inc. Ownership
Holder
Name
Confidence
Evidence
APUS-OWNER-HEMENWAY-TRUST-CO-LLC
Hemenway Trust Co LLC
90%
13F overlay lists Hemenway Trust Co LLC as top holder; 6 tracked holders.
Apimeds Pharmaceuticals US, Inc. Extended Supply Chain Network
